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Abstract
Background: Diabetic peripheral neuropathy (DPN) has been prevalent and discussed, and nerve conduction
studies (NCS) has been continued. We have checked NCS using recently introduced useful DPN-Check device.
Subjects and Methods: The subjects were 66 patients (pts) classified into 4 groups according to existence of
diabetes mellitus (DM) and hemodialysis (HD); Group1: DM (+), HD (+) in 15 pts, group 2: DM (-), HD (+) in 15 pts,
group 3: DM (+), HD (-) in 20 pts, group 4: 16 healthy controls. Methods included measurements of sural nerve
conduction velocity (SNCV) and sural nerve action potential (SNAP) using HDN-1000.
Results: Average age in each group was 64.4 years to 72.6 years. SNCV value of 4 group in average was 37.1
m/sec, 46.3 m/sec, 49.3 m/sec, 53.2 m/sec, respectively, and value of group 1 was significantly lower than those of
group 2,3,4 (p<0.01). Similarly, average SNAP was 4.1 μV, 8.7 μV, 8.0 μV, 21.6 μV, respectively, and group 1,2,3
were significantly lower than group 4 (p<0.01). There was significant correlation between SNCV and SNAP in all
subjects (p<0.01). Significant correlations were shown between DM duration and SNCV, and DM duration and SNAP
(p<0.01).
Discussion and Conclusion: SNCV and SNAP were measured successfully and easily by HDN-1000, indicating
clinical availability. Obtained data suggested that 1) SNCV is not significantly decreased due to only uremic
neuropathy, 2) SNCV is significantly decreased in patients with both HD and DM, 3) SNAP is significantly decreased
in patents with DM for years and 4) SNAP would be remarkably decreased when HD is in addition to DM. These
results would become the basal data of future NCS for DM and HD.
Keywords: Diabetic peripheral neuropathy; Nerve conduction
studies; Sural nerve conduction velocity; Sural nerve action potential;
Diabetes mellitus; Hemodialysis
Abbreviations: DPN: Diabetic Peripheral Neuropathy; NCS: Nerve
Conduction Studies; SNCV: Sural Nerve Conduction Velocity; SNAP:
Sural Nerve Action Potential; DM: Diabetes Mellitus; HD:
Hemodialysis; UN: Uremic Neuropathy; LCD: Low Carbohydrate Diet;
CCM: Corneal Confocal Microscopy; IENFD: Intra-Epidermal Nerve
Fiber Density; CTS: Carpal Tunnel Syndrome; MN: Median
Neuropathy
Introduction
Diabetes mellitus (DM) has been increasing worldwide. The
prevalence of the diabetics is 8.8 % in 2015, and it will rise to 10.4% in
2040 [1,2]. Neuropathy is one of common and important micro-
angiopathic complication, and observed in high percentage of diabetic
patients [3,4]. Historically speaking, diabetic peripheral neuropathy
(DPN) has been widely known and prevalent. In order to clarify the
influence of hyperglycemia on the progression of diabetic neuropathy,
nerve conduction velocity was formerly measured at median, peroneal
and tibial motor nerves, supporting the hypothesis of a metabolic
component to diabetic neuropathy [5,6]. DPN has been actually
diagnosed based on medical history, physical exam and some simple
tests [6,7]. While this testing is easy to perform, it is limited in terms of
its accuracy. Nerve conduction studies (NCS) has been introduced, but
its complexity and cost have excluded their use in a routine evaluation
[8,9]. Recently, advances in technology have enabled us to perform
NCS easily. By sural nerve in calf and ankle, simple and useful DPN-
Check device showed accurate NCS for the assessment of DPN [10,11].
Authors have reported lots of studies for years concerning diabetes
including low carbohydrate diet (LCD), lipid metabolism, exercise, and
ketone bodies [12-15]. In current study, we investigated NCS in
patients with DM and/or with chronic hemodialysis (HD).
Subjects and Methods
We enrolled 66 subjects in current study, including 50 patients and
16 normal healthy subjects. Subjects were categorized into 4 groups
according to the existence of DM and/or on hemodialysis (HD). The
groups were as follows. Group 1 includes 15 diabetic patients with HD,
group 2 includes 15 patients with HD and without DM, group 3
includes 20 diabetic patients without HD and group 4 includes 16
normal subjects which age were matched to that of group 3 (Table 1).
Methods include the measurement of sural nerve conduction velocity
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(SNCV) and sural nerve action potential (SNAP) in the lower calf and
ankle. We used recently introduced simple and precise medical device,
HDN-1000 which was developed by NeuroMetrics Inc., USA with
registered No. 226AABZI00091000. This device has been based on
validated technologies [16,17], and has lots of research results with
high sensitivity and reproducibility, and clinically simple and useful
measurements [18,19]. The procedure on the examination is simple
and performed within a few minutes. The small device gives electrical
stimulation on the back side of the ankle, and can measure with a
biosensor installed 9.22 cm ahead of the stimulation probe. The
standard normal range has been adequate from various research,
which were more than 48 m/sec for the SNCV, and more than 6 μV for
SNAP [8,11,20].
Statistical analyses
In current study, obtained data was shown as the mean ± standard
deviation (SD) and also median, quartile of 25% and 75% in
biomarkers. For statistical analyses, correlation coefficients were
calculated using Pearson or Spearman test of the Microsoft Excel
analytical tool, which is Four steps Excel Statistics 4th edition [21].
Intergroup comparisons were made using the Wilcoxon rank sum test
or the Bonferroni multiple comparisons (Lambert method). A
significance level of less than 5% obtained using a two-tailed test was
considered to be statistically significant.
Results
Subjects of 4 groups
The data of 66 subjects were shown in Table 1. Average age in each
group was 64.4 years to 72.6 years Median DM duration was 23.5 years
and 14.8 years in Group 1 and 3, and median HD duration was 6.0
years and 8.6 years in Group 1 and 2, respectively. When calculated by
mean ± standard deviation, SNCV value in group 1 was significantly
lower than those of group 2, 3, 4 (p<0.01). SNAP values in group 1, 2, 3
were significantly lower than that of group 4 (p<0.01).
 Group 1 Group 2 Group 3 Group 4
Categorization from treatment
Diabetic treatment + - + -
Hemodialysis treatment + + - -
Subjects
number 15 15 20 16
male/female 7/8 5/10 9/11 8/8
average age (year) 67.8 72.6 67.9 64.4
standard deviation 6 6.9 15.9 14.6
median 68 74 70.5 62
quartile 25% 63 67 60.1 52.8
qauartile 75% 73.0 76.0 80.5 74.8
History of diabetes mellitus (year)
median 23.5 - 14.8 -
quartile 25% 13.3 - 6.6 -
qauartile 75% 23.0 - 14.0 -
History of hemodialysis (year)
median 6.0 8.6 - -
quartile 25% 3.1 5.9 - -
qauartile 75% 5.9 10.9 - -
SN conduction velocity (m/sec)
average 37.1a 46.3 49.3 53.2
standard deviation 14.5 10.6 3.6 3
median 38 49 49.5 53.5
quartile 25% 22 45.5 47 50.8
qauartile 75% 51 53 52 56
SN action potential (µV)
average 4.1b 8.7b 8.1b 20.6
standard deviation 2.4 5.3 4.9 5.5
median 3 9 6.5 21.5
quartile 25% 2 3 4 18.5
qauartile 75% 5.5 11.5 11.3 24.3
a Value of group 1 is significantly lower than that of group 2,3,4 ( p<0.01);
b Value of group 1,2,3 is significantly lower than that of group 4 ( p<0.01)
Table 1: Classification and general data of the subjects.
Correlation between SNCV and SNAP
Correlation between SNCV and SNAP was shown in Figure 1. This
includes all data from 4 groups. Both revealed significant correlation
and data from each group showed close distribution, respectively.
Figure 1: Correlation between sural nerve conduction velocity
(SNCV) and sural nerve action potential (SNAP); Group 1: DM (+),
HD (+); Group 2: DM (-), HD (+); Group 3: DM (+), HD (-); Group
4: DM (-), HD (-).
Correlation between DM duration and NCS
Correlation between diabetic duration and SNCV or SNAP was
shown in Figure 2a and 2b.
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It showed significant correlation between both biomarkers (p<0.01).
Figure 2: Correlation between diabetic duration and NCS; 2a DM duration and SNCV; Fig 2b DM duration and SNAP; Group 1: DM (+), HD
(+); Group 3: DM (+), HD (-).
Correlation between HD duration and NCS
Correlation between HD duration and SNCV or SNAP was shown
in Figure 3a and 3b.
There was no significant correlation in each analysis.
Figure 3: Correlation between hemodialysis duration and NCS; 3a-HD duration and SNCV; 3b-HD duration and SNAP; Group 1: DM (+),
HD (+); Group 2: DM (-), HD (+).
Discussion
Formerly, there was a relationship between cardiac autonomic
neuropathy and coronary artery disease [22-24]. Additional studies
revealed a relationship between peripheral neuropathy and coronary
artery disease [24-26].
The relationship between the presence of neuropathy were assessed
by NCS and future mortality in diabetic patients [27,28]. Mortality
were increased when a patient had neuropathic history and higher
initial A1C, in which neuropathic history nearly doubled the mortality
risk [hazard ratio of 1.95] whereas an A1C of >8.5% had 1.64 hazard
ratio [27]. Adjusted for other common risk factors, the hazard from
neuropathy for all-cause mortality was 4.44 and for diabetes-related
mortality were 11.82. Consequently, neuropathy increased the risk of
diabetes-related mortality more than 10-fold when corrected for other
risk factors [28].
According to the MONICA/KORA Augsburg Surveys, the
prevalence of polyneuropathy was 28.0% in the diabetic subjects,
13.0% in impaired glucose tolerance (IGT), 11.3% in impaired fasting
glucose (IFG), and 7.4% in normal glucose tolerance (NGT) [25].
Sural nerve is one of a distal sensory nerve. It innervates at lateral
and posterior third of leg and lateral aspect of foot and heel and lateral
portion of the ankle. The characteristic point is that sural nerve is
sensitive to DPN, which is recognized as a biomarker of DPN. [20,29].
In recent years, a new device of HDN-1000 was released, which can
measure the nerve conduction velocity of the sural nerve easily. As to
the results of SNCV and SNAP by HDN-1000, both showed nearly
equivalent numerical values as compared with the conventional NCT,
and their usefulness has been evaluated [11]. It included lots of
research results based on validated technologies [8,16,17,30].
Citation: Kato Y, Bando H, Fujikawa T, Narutaki M, Yamamoto M, et al. (2017) Influence of Diabetes and Hemodialysis Against Nerve
Conduction Studies. J Gen Pract (Los Angel) 5: 343. doi:10.4172/2329-9126.1000343
Page 3 of 5
J Gen Pract (Los Angel), an open access journal
ISSN:2329-9126
Volume 5 • Issue 6 • 1000343
Clinical data were summarized as follows: 1) sural nerve conduction
is a standard, quantitative biomarker of DPN [8], 2) DPN was detected
to be with high diagnostic sensitivity [7], 3) it showed abnormalities
indicative of subclinical DPN [18], it correlated to morphological
severity of DPN [3,7,30], 4) detectable sural response was suggestive of
low foot ulcer risk [31] and 5) predictive of concurrent micro vascular
complications [32].
In clinical application of HDN-1000, it was convenient for repeated
peripheral nerve function measurements, as well as reduced
invasiveness and stress to the patient [19].
As to diabetic neuropathy, it has been known that carpal tunnel
syndrome (CTS) frequently occurs in diabetic patients [33,34]. Its
characteristics are that many cases are pointed out as median
neuropathy (MN) at the wrist in asymptomatic NCS. MN is frequently
observed in early stages when DPN was not observed, then it may be
regarded as an early lesion of DPN [35].
There are remarkable decrease of SNAP in group 1 and 3 compared
with that of group 4. One of the reasons for decreased SNAP in
diabetics would be from decreased intra-epidermal nerve fiber density
(IENFD) [36]. IENFD can be observed with a confocal microscope, by
a 3 mm diameter punching needle biopsies at 10 cm above the ankle of
the lower extremity with fixes and immunostaining. The value of
IENFD falls from the early stage of DPN and declines in correlation
with the progression of stage [37].
In previous reports, peripheral neuropathy in HD patients has been
a devastating uremic complication which causes debilitating pain and
limitation of movement [38]. Out of 28 HD patients with 31 months
duration of HD in median, 8 patients (29%) were diabetics, and all
patients exhibited overt peripheral neuropathy [38].
As another report, severe uremic neuropathy (UN) was seen in
16.4% of HD by both the Michigan Neuropathy Score Instrument
(MNSI) and the electroneurographic (ENG) lower limbs examination
[39]. End-stage renal failure in DM is often associated with severe
distal motor and sensory deficits [40]. Peripheral neuropathy in
patients with DM and HD may be correlated with hyperkalaemia and
nerve dysfunction deterioration [41].
In current study, results were revealed that SNCV in group 1 was
significantly lower than that of group 2, 3 and SNAP in group 1 and 2
were significantly decreased compared with that of group 4. Taking our
data and previous reports into consideration, it is suggested that 1)
SNCV is not significantly decreased due to only uremic neuropathy, 2)
SNCV is significantly decreased in patients with both HD and DM, 3)
SNAP is significantly decreased in patents with DM for years and 4)
SNAP would be decreased more when HD is in addition to DM. On
contrast, there is limitation of study because of small number of
subjects and affecting various influences of biomarkers.
Conclusion
In this study, decreased SNCV and SNAP were shown in patients
with diabetes and/or with chronic hemodialysis. The data may suggest
the pathophysiological influence of DM and HD for deterioration of
neuropathy. These results would become the basal data of future
investigation for NCS for DM and HD.
Ethical Considerations
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